CL2016001895A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
CL2016001895A1
CL2016001895A1 CL2016001895A CL2016001895A CL2016001895A1 CL 2016001895 A1 CL2016001895 A1 CL 2016001895A1 CL 2016001895 A CL2016001895 A CL 2016001895A CL 2016001895 A CL2016001895 A CL 2016001895A CL 2016001895 A1 CL2016001895 A1 CL 2016001895A1
Authority
CL
Chile
Prior art keywords
compounds
pirazolo
pirimidin
pirrolo
amina
Prior art date
Application number
CL2016001895A
Other languages
English (en)
Inventor
Xiao Ding
Qian Liu
Yingxia Sang
Luigi Piero Stasi
Zehong Wan
Baowei Zhao
Colin Michael Edge
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2016001895A1 publication Critical patent/CL2016001895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

COMPUESTOS DERIVADOS DE PIRAZOLO PIRROLO[2,3-D]PIRIMIDIN-2-AMINA, COMO INHIBIDORES DE LA ACTIVIDAD DE LAS CINASAS LRRK2; COMPOSICIÓN FARMACÉUTICA; Y SU USO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON.
CL2016001895A 2014-01-29 2016-07-26 Compuestos CL2016001895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29

Publications (1)

Publication Number Publication Date
CL2016001895A1 true CL2016001895A1 (es) 2016-12-09

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001895A CL2016001895A1 (es) 2014-01-29 2016-07-26 Compuestos

Country Status (20)

Country Link
US (2) US10087186B2 (es)
EP (1) EP3099695B1 (es)
JP (1) JP6422986B2 (es)
KR (1) KR20160106622A (es)
CN (1) CN105940004B (es)
AU (2) AU2015210593A1 (es)
CA (1) CA2937431A1 (es)
CL (1) CL2016001895A1 (es)
CR (1) CR20160348A (es)
DO (2) DOP2016000195A (es)
EA (1) EA029774B1 (es)
ES (1) ES2802174T3 (es)
IL (1) IL246579B (es)
MA (1) MA39219B1 (es)
MX (1) MX367370B (es)
PE (1) PE20161443A1 (es)
PH (1) PH12016501307A1 (es)
SG (1) SG11201605342UA (es)
UA (1) UA118369C2 (es)
WO (1) WO2015113452A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
ES2717757T3 (es) 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
CN105940004B (zh) 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
BR112019015278A2 (pt) * 2017-01-25 2020-04-14 Glaxosmithkline Ip Dev Ltd compostos
KR20180097162A (ko) 2017-02-22 2018-08-30 국립암센터 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
RU2730849C1 (ru) * 2017-03-23 2020-08-26 Даегу-Гиеонгбук Медикал Инновейшн Фаундейшн Производное пирроло-пиридинового соединения, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения заболеваний, связанных с протеинкиназой
JP7230053B2 (ja) * 2017-12-05 2023-02-28 オスコテック インコーポレイテッド Ｌｒｒｋ２阻害剤としてのピロロ（ピラゾロ）ピリミジン誘導体
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CA3114198A1 (en) 2018-09-25 2020-04-02 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
CA3197034A1 (en) * 2020-10-29 2022-05-05 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2584489C (en) 2004-10-21 2014-07-22 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
EP1948658A1 (en) 2005-10-13 2008-07-30 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
EP2483254B1 (en) 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8815882B2 (en) * 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
WO2012143144A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
PE20141228A1 (es) * 2011-09-22 2014-10-01 Pfizer Derivados de pirrolopirimidina y purina
EP2785381B1 (en) * 2011-11-30 2016-05-18 F.Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
RU2637948C2 (ru) 2012-05-03 2017-12-08 Дженентек, Инк. Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 (lrrk2) для применения при лечении болезни паркинсона
BR112014026952B1 (pt) 2012-05-03 2022-03-15 Genentech, Inc Derivados de aminopirimidina pirazol e composição que os compreende
CN105732639A (zh) * 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
ES2717757T3 (es) 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
CN105940004B (zh) 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物

Also Published As

Publication number Publication date
MA39219A1 (fr) 2017-09-29
US10087186B2 (en) 2018-10-02
MX2016009893A (es) 2016-10-31
AU2015210593A1 (en) 2016-07-07
CA2937431A1 (en) 2015-08-06
WO2015113452A1 (en) 2015-08-06
EP3099695B1 (en) 2020-04-08
US10618901B2 (en) 2020-04-14
AU2018200277A1 (en) 2018-02-01
PE20161443A1 (es) 2017-01-06
PH12016501307B1 (en) 2016-08-15
PH12016501307A1 (en) 2016-08-15
KR20160106622A (ko) 2016-09-12
ES2802174T3 (es) 2021-01-15
MX367370B (es) 2019-08-16
EP3099695A4 (en) 2017-07-12
DOP2016000195A (es) 2016-10-31
MA39219B1 (fr) 2018-11-30
US20170015668A1 (en) 2017-01-19
IL246579A0 (en) 2016-08-31
SG11201605342UA (en) 2016-08-30
EP3099695A1 (en) 2016-12-07
UA118369C2 (uk) 2019-01-10
IL246579B (en) 2019-05-30
CN105940004A (zh) 2016-09-14
EA201691514A1 (ru) 2016-12-30
EA029774B1 (ru) 2018-05-31
JP6422986B2 (ja) 2018-11-14
CR20160348A (es) 2017-04-28
CN105940004B (zh) 2018-02-02
AU2018200277B2 (en) 2019-09-26
US20180354956A1 (en) 2018-12-13
DOP2019000010A (es) 2019-03-15
JP2017504631A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
CL2016001895A1 (es) Compuestos
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
SV2018005610A (es) Derivados de oxopiridina sustituidos
CR20170478A (es) Compuestos novedosos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112015019508A2 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002060A1 (es) Compuestos.